CA2544532C - Compositions comprising polypeptides - Google Patents

Compositions comprising polypeptides Download PDF

Info

Publication number
CA2544532C
CA2544532C CA2544532A CA2544532A CA2544532C CA 2544532 C CA2544532 C CA 2544532C CA 2544532 A CA2544532 A CA 2544532A CA 2544532 A CA2544532 A CA 2544532A CA 2544532 C CA2544532 C CA 2544532C
Authority
CA
Canada
Prior art keywords
polypeptide
multimeric
antigen
chromatographic material
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2544532A
Other languages
English (en)
French (fr)
Other versions
CA2544532A1 (en
Inventor
Robert Hofmeister
Nadja Prang
Andreas Wolf
Frank Hanakam
Thomas Urbig
Christian Itin
Patrick Baeuerle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of CA2544532A1 publication Critical patent/CA2544532A1/en
Application granted granted Critical
Publication of CA2544532C publication Critical patent/CA2544532C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2544532A 2003-11-28 2004-11-26 Compositions comprising polypeptides Expired - Lifetime CA2544532C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03027511.9 2003-11-28
EP03027511 2003-11-28
PCT/EP2004/013445 WO2005052004A2 (en) 2003-11-28 2004-11-26 Compositions comprising polypeptides

Publications (2)

Publication Number Publication Date
CA2544532A1 CA2544532A1 (en) 2005-06-09
CA2544532C true CA2544532C (en) 2015-06-16

Family

ID=34626385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2544532A Expired - Lifetime CA2544532C (en) 2003-11-28 2004-11-26 Compositions comprising polypeptides

Country Status (18)

Country Link
US (1) US10000574B2 (forum.php)
EP (2) EP1691833B1 (forum.php)
AT (1) ATE459374T1 (forum.php)
AU (1) AU2004293182B2 (forum.php)
BE (1) BE2016C023I2 (forum.php)
CA (1) CA2544532C (forum.php)
CY (2) CY1110689T1 (forum.php)
DE (1) DE602004025840D1 (forum.php)
DK (1) DK1691833T3 (forum.php)
ES (1) ES2341252T3 (forum.php)
FR (1) FR16C1000I2 (forum.php)
HU (1) HUS1600019I1 (forum.php)
LU (1) LU93067I2 (forum.php)
NL (1) NL300807I2 (forum.php)
PL (1) PL1691833T3 (forum.php)
PT (1) PT1691833E (forum.php)
SI (1) SI1691833T1 (forum.php)
WO (1) WO2005052004A2 (forum.php)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658557C (en) 2006-08-14 2015-12-01 Xencor, Inc. Optimized antibodies that target cd19
DK2066349T3 (da) * 2006-09-08 2012-07-09 Medimmune Llc Humaniseret anti-cd19-antistoffer og anvendelse heraf i behandling af tumorer, transplantation og autoimmune sygdomme
US9308257B2 (en) * 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
EP3412687B1 (en) 2010-10-27 2020-03-18 Amgen Research (Munich) GmbH Methods for treating dlbcl
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
RU2632647C2 (ru) 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
EP3680254A1 (en) 2013-12-17 2020-07-15 F. Hoffmann-La Roche AG Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
EP3083690A1 (en) 2013-12-17 2016-10-26 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
SG10201913324PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
KR102709593B1 (ko) 2014-11-05 2024-09-26 제넨테크, 인크. 박테리아 내 2쇄 단백질을 생산하는 방법
EP3753948A1 (en) 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria
JP2018508481A (ja) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体
KR20180013881A (ko) 2015-05-29 2018-02-07 제넨테크, 인크. 암에서의 pd-l1 프로모터 메틸화
CN116327953A (zh) 2015-06-17 2023-06-27 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3377103B2 (en) 2015-11-19 2025-03-12 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
JP7325186B2 (ja) 2015-12-09 2023-08-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CN108368179B (zh) 2016-01-08 2022-08-23 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
AU2018276419A1 (en) 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
MX2019006955A (es) 2016-12-19 2019-08-01 Hoffmann La Roche Terapia de combinacion con agonistas de 4-1bb orientados (cd137).
MX2019006954A (es) 2016-12-20 2019-08-01 Hoffmann La Roche Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
BR112020007630A2 (pt) 2017-11-01 2020-11-17 F. Hoffmann-La Roche Ag anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40
PL3765489T3 (pl) 2018-03-13 2025-02-10 F. Hoffmann-La Roche Ag Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
CA3102562A1 (en) * 2018-06-07 2019-12-12 Cullinan Management, Inc. Multi-specific binding proteins and methods of use thereof
AU2019342133B8 (en) 2018-09-21 2025-08-07 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
CN113260626B (zh) 2018-11-05 2024-09-13 豪夫迈·罗氏有限公司 在原核宿主细胞中产生双链蛋白质的方法
WO2020221792A1 (en) 2019-04-30 2020-11-05 Amgen Research (Munich) Gmbh Means and methods of treating burkitt lymphoma or leukemia
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
CA3161283A1 (en) 2019-12-11 2021-06-17 Cullinan Oncology, Inc. Anti-cd19 antibodies and multi-specific binding proteins
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
KR102453073B1 (ko) * 2020-08-14 2022-10-11 건국대학교 글로컬산학협력단 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
JP7717832B2 (ja) 2021-04-10 2025-08-04 ジェンマブ エー／エス Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
US20250066490A1 (en) 2021-04-23 2025-02-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4083061A1 (en) * 2021-04-30 2022-11-02 Kilometro Rosso SPA Fusion proteins and use thereof in the treatment of membranous nephropathy
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
EP4496631A1 (en) 2022-03-23 2025-01-29 F. Hoffmann-La Roche AG Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
KR20250004776A (ko) 2022-04-13 2025-01-08 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
CN120152989A (zh) 2022-11-03 2025-06-13 豪夫迈·罗氏有限公司 抗cd19/抗cd28双特异性抗体的组合疗法
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
US20250115680A1 (en) 2023-09-26 2025-04-10 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025222129A2 (en) 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE69233068T2 (de) 1991-02-27 2004-01-22 Micromet Ag Serin-reiche peptidlinker
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
PL199747B1 (pl) 1998-04-21 2008-10-31 Micromet Ag Jednołańcuchowy wielofunkcyjny polipeptyd, polinukleotyd, wektor, komórka, sposób wytwarzania polipeptydu, kompozycja, zastosowanie polipeptydu lub wektora lub polinukleotydu i zastosowanie polinukleotydu lub wektora oraz sposób identyfikacji aktywatorów lub inhibitorów aktywacji lub stymulacji komórek T
US20020142964A1 (en) * 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies

Also Published As

Publication number Publication date
BE2016C023I2 (forum.php) 2023-12-18
DE602004025840D1 (de) 2010-04-15
AU2004293182A1 (en) 2005-06-09
SI1691833T1 (sl) 2010-06-30
ATE459374T1 (de) 2010-03-15
CY1110689T1 (el) 2015-06-10
CY2016010I1 (el) 2016-08-31
EP1691833A2 (en) 2006-08-23
HUS1600019I1 (hu) 2016-06-28
PT1691833E (pt) 2010-06-08
ES2341252T3 (es) 2010-06-17
FR16C1000I2 (fr) 2017-02-03
EP2186527A1 (en) 2010-05-19
WO2005052004A2 (en) 2005-06-09
CA2544532A1 (en) 2005-06-09
PL1691833T3 (pl) 2010-08-31
LU93067I2 (fr) 2016-07-11
EP1691833B1 (en) 2010-03-03
WO2005052004A3 (en) 2006-03-09
DK1691833T3 (da) 2010-05-03
AU2004293182B2 (en) 2010-02-18
US10000574B2 (en) 2018-06-19
NL300807I2 (forum.php) 2016-10-13
US20070249529A1 (en) 2007-10-25
CY2016010I2 (el) 2016-08-31
FR16C1000I1 (forum.php) 2016-06-24

Similar Documents

Publication Publication Date Title
CA2544532C (en) Compositions comprising polypeptides
JP7262597B2 (ja) 二重特異性抗体及びその作製方法と使用
AU2016336866B2 (en) Multivalent Fv antibodies
RU2753882C2 (ru) Трифункциональная антигенсвязывающая молекула
Morris et al. Development and characterization of recombinant human Fc: OX40L fusion protein linked via a coiled-coil trimerization domain
CA3114451A1 (en) T cell receptor for identifying ssx2 antigen
KR20170041697A (ko) 이중특이적 cd33 및 cd3 결합 단백질
RS61590B1 (sr) Monoklonsko antitelo protiv ctla4 ili njegov antigen-vezujući fragment, medicinska kompozicija i upotreba
CA2924252A1 (en) Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions
ZA200506282B (en) Trimeric polypeptide construct to induce an enduring T cell response
KR20180014066A (ko) 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
CA3108466A1 (en) T cell receptor for identifying afp antigen
CN118871464A (zh) 包含lrrc15抗原结合结构域的多特异性t细胞接合剂
CN116635071A (zh) 抗tspan8-抗cd3双特异性抗体和抗tspan8抗体
JP2024514246A (ja) Ｃｌｄｎ１８．２抗原結合タンパク質およびその使用
CN108840932A (zh) 一种pd-1特异性抗体及其抗肿瘤应用
CN109422814A (zh) 一种抗La/SSB嵌合体抗原修饰的NK细胞、其制备方法及其应用
CN110872356B (zh) 双特异性抗体及其使用方法
CN111484554B (zh) 一种靶向4-1bb的肿瘤抑制性抗体及其应用
RU2785766C2 (ru) Мультивалентные fv-антитела
RU2785766C9 (ru) Мультивалентные fv-антитела
CN120775047A (zh) 靶向Claudin18.2的抗体及其应用
NZ745376B2 (en) Method and compositions for cellular immunotherapy
NZ745374B2 (en) Method and compositions for cellular immunotherapy

Legal Events

Date Code Title Description
EEER Examination request